ALS Medical Diagnosis: Understanding Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, is a progressive neurodegenerative disease that impacts motor neurons in the brain and spinal cord. These motor neurons are crucial nerve cells that control voluntary muscle movement, enabling us to walk, speak, breathe, swallow, and more. When ALS affects these neurons, muscle control is gradually lost. The condition worsens over time, making early and accurate ALS medical diagnosis vital for patient care and management.

Recognizing ALS Symptoms: Early Signs and Progression

The presentation of ALS symptoms is highly variable; no two individuals experience the disease exactly the same way. The symptoms depend significantly on which motor neurons are initially affected and the pattern of disease progression. Generally, ALS onset is characterized by muscle weakness that gradually spreads and intensifies over time. Recognizing these early symptoms is the first step in seeking an ALS medical diagnosis.

Common early symptoms of ALS may include:

• Difficulties with mobility and daily activities: This can manifest as trouble walking, clumsiness, or struggling with tasks that were once simple, like buttoning clothes or turning a key.
• Unexplained falls and tripping: Leg weakness can lead to instability and an increased frequency of falls.
• Localized weakness: Often starting in the limbs, this might be felt as weakness in the legs, feet, or ankles, or hand weakness impacting grip and dexterity.
• Speech and swallowing issues: Slurred speech (dysarthria) or difficulty swallowing (dysphagia) can be among the first noticeable symptoms.
• Muscle cramps and twitching (fasciculations): These involuntary muscle contractions can occur in the arms, shoulders, and tongue, often accompanied by weakness.
• Emotional lability: Sudden and uncontrollable episodes of crying, laughing, or yawning that are disproportionate to the situation.
• Cognitive and behavioral changes: While less common in early stages, some individuals may experience subtle changes in thinking or behavior.

It’s important to note that ALS frequently begins in the hands, feet, arms, or legs before spreading to other parts of the body. As more motor neurons die, muscle weakness intensifies, eventually affecting essential functions like chewing, swallowing, speaking, and breathing.

Pain is typically not a prominent symptom, particularly in the early stages of ALS. Similarly, bladder control and sensory functions like taste, smell, touch, and hearing are usually unaffected.

Unraveling the Causes of ALS: Genetic and Environmental Factors

ALS occurs due to the degeneration and eventual death of motor neurons. These critical nerve cells are divided into two types:

• Upper motor neurons: Extending from the brain to the spinal cord.
• Lower motor neurons: Extending from the spinal cord to muscles throughout the body.

In ALS, both upper and lower motor neurons progressively deteriorate, losing their ability to transmit signals to muscles. This disruption in nerve signaling leads to muscle weakness, atrophy, and loss of function.

While the precise cause of ALS remains unknown for most individuals, research suggests a complex interplay of genetic and environmental factors.

Genetic Factors: Approximately 10% of ALS cases are classified as familial or hereditary ALS, meaning they are directly linked to inherited gene mutations. In these cases, a risk gene is passed down from a family member. For individuals with hereditary ALS, there is a 50% chance that their children will inherit the same gene mutation. Researchers have identified several genes associated with familial ALS, and genetic testing can be valuable in these cases, both for ALS medical diagnosis confirmation and for family planning.

Environmental Factors: For the majority of ALS cases (sporadic ALS), no clear genetic cause is identified. Research is ongoing to understand the role of environmental factors in triggering or accelerating the disease process. Established and suspected environmental risk factors include:

• Smoking: Strong evidence indicates that smoking is an environmental risk factor for ALS. Women who smoke, particularly post-menopausal women, appear to have an even higher risk.
• Exposure to environmental toxins: Some studies suggest a potential link between ALS and exposure to certain toxins like lead or other substances in occupational or residential settings. However, no specific agent has been consistently linked to ALS across studies.
• Military service: Military personnel have been shown to have a higher risk of developing ALS. The reasons for this are not fully understood but may involve exposure to specific metals or chemicals, traumatic injuries, viral infections, or intense physical exertion during service.

Risk Factors for ALS: Who is More Susceptible?

While ALS can affect anyone, certain factors increase the likelihood of developing the disease. Established risk factors include:

• Age: The risk of ALS increases with age, peaking around age 75. It is most commonly diagnosed between the ages of 60 and the mid-80s.
• Genetics: As discussed, having a family history of ALS significantly increases risk due to the possibility of inheriting gene mutations.
• Sex: Before the age of 65, men are slightly more likely to develop ALS than women. However, this gender difference diminishes after age 70.

ALS Complications: Managing the Progressive Nature of the Disease

As ALS progresses, it leads to a range of complications that significantly impact quality of life and require comprehensive management.

Breathing Problems: Weakness of the respiratory muscles is a major complication of ALS. Over time, it can lead to respiratory insufficiency. Individuals may initially require non-invasive ventilation, such as mask ventilation, particularly during sleep. In advanced stages, a tracheostomy, a surgical procedure creating an opening in the neck for direct airway access, might be considered for more effective ventilation. Respiratory failure is the most common cause of death in ALS. The median survival after ALS medical diagnosis is typically between 14 to 18 months, although survival can vary greatly, with some individuals living for 10 years or more.

Speech Problems (Dysarthria): Muscle weakness affecting speech articulation is common in ALS. Initially, this may manifest as slow speech or occasional slurring. As the disease progresses, speech clarity deteriorates, potentially leading to unintelligible speech. Communication aids and technologies become essential for maintaining communication.

Eating Problems (Dysphagia): Weakness in the muscles involved in swallowing can lead to difficulties eating and drinking. This increases the risk of malnutrition, dehydration, and aspiration pneumonia (when food or liquid enters the lungs). Feeding tubes may be necessary to ensure adequate nutrition and hydration and minimize these risks.

Cognitive Changes and Dementia: While primarily a motor neuron disease, ALS can, in some cases, affect cognitive function. Some individuals with ALS experience language and decision-making difficulties. A subset may develop frontotemporal dementia (FTD), a form of dementia affecting behavior and personality.

Seeking ALS Medical Diagnosis and Care

If you or someone you know is experiencing symptoms suggestive of ALS, seeking prompt ALS medical diagnosis is crucial. Diagnosis typically involves a neurological examination, electromyography (EMG) to assess muscle and nerve function, nerve conduction studies, MRI of the brain and spinal cord to rule out other conditions, and blood and urine tests. While there is currently no cure for ALS, early diagnosis allows for timely initiation of management strategies to alleviate symptoms, improve quality of life, and extend survival. A multidisciplinary approach involving neurologists, pulmonologists, speech therapists, occupational therapists, physical therapists, dietitians, and social workers is essential for comprehensive ALS care.

References:

1. Just what is ALS? ALS Association. https://www.als.org/understanding-als/what-is-als. Accessed Feb. 16, 2023.
2. Ferri FF. Amyotrophic lateral sclerosis. In: Ferri’s Clinical Advisor 2023. Elsevier; 2023. https://www.clinicalkey.com. Accessed Feb. 16, 2023.
3. Elman LB, et al. Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease. https://www.uptodate.com/contents/search. Accessed Feb. 16, 2023.
4. Preston DC, et al. Amyotrophic lateral sclerosis and its variants. In: Electromyography and Neuromuscular Disorders. 4th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Feb. 16, 2023.
5. Elman LB, et al. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. https://www.uptodate.com/contents/search. Accessed Feb. 16, 2023.
6. Goldman L, et al., eds. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Goldman-Cecil Medicine. 26th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Feb. 16, 2023.
7. Amyotrophic lateral sclerosis (ALS) fact sheet. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Amyotrophic-Lateral-Sclerosis-ALS-Fact-Sheet. Accessed Feb. 16, 2023.
8. Environmental factors. ALS Association. https://www.als.org/research/research-we-fund/scientific-focus-areas/environmental-factors. Accessed Feb. 16, 2023.
9. After the ALS diagnosis: Coping with the ‘new normal.’ ALS Association. http://www.alsa.org/als-care/resources/publications-videos/resource-guides/. Accessed Feb. 16, 2023.
10. Ami TR. Allscripts EPSi. Mayo Clinic. Dec. 22, 2022.
11. Dharmadasa T, et al. Genetic testing in motor neuron disease. Practical Neurology. 2022; doi:10.1136/practneurol-2021-002989.
12. Mehta P, et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2022; doi:10.1080/21678421.2021.2023190.
13. Relyvrio (approval letter). New Drug Application 216660. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed Feb. 17, 2023.
14. Yamakawa M, et al. Demographics, clinical characteristics and prognostic factors of amyotrophic lateral sclerosis in Midwest. Muscle & Nerve. 2022; doi:10.1002/mus.27450.
15. Van Blitterswijk M, et al. How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: Can we learn from other noncoding repeat expansion disorders? Current Opinion in Neurology. 2012; doi:10.1097/WCO.0b013e32835a3efb.
16. ALS certified centers and clinics. ALS Association. https://www.als.org/local-support/certified-centers-clinics?search_api_fulltext=Mayo+Clinic. Accessed Dec. 8, 2022.
17. Barry RL, et al. Ultra-high field (7T) functional magnetic resonance imaging in amyotrophic lateral sclerosis: A pilot study. NeuroImage Clinical. 2021; doi:10.1016/j.nicl.2021.102648.
18. Dorst J, et al. Clinical studies in amyotrophic lateral sclerosis. Current Opinion in Neurology. 2022; doi:10.1097/WCO.0000000000001099.
19. Oskarsson BE (expert opinion). Mayo Clinic. Jan. 6, 2023.
20. Sun Y, et al. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics. 2023; doi:10.1080/14737175.2023.2174018.
21. Sturmey E, et al. Blood biomarkers in ALS: Challenges, applications and novel frontiers. Acta Neurologica Scandinavica. 2022; doi:10.1111/ane.13698.
22. Soga T, et al. Long-term outcomes after surgery to prevent aspiration for patients with amyotrophic lateral sclerosis. BMC Neurology. 2022; doi:10.1186/s12883-022-02619-z.
23. Rutkove SB, et al. Differential diagnosis of peripheral nerve and muscle disease. https://www.uptodate.com/contents/search. Accessed March 9, 2023.
24. National Amyotrophic Lateral Sclerosis (ALS) Registry. Centers for Disease Control and Prevention. https://www.cdc.gov/als/GeneralPublic_AboutRegistry.html. Accessed March 9, 2023.
25. Johnson SA (expert opinion). Mayo Clinic. March 8, 2023.
26. Staff NP (expert opinion). Mayo Clinic. March 9, 2023.
27. Oskarsson BE (expert opinion). Mayo Clinic. Feb. 21, 2023.